{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:49:13Z","timestamp":1790682553316,"version":"4.1.0"},"reference-count":94,"publisher":"Baishideng Publishing Group Inc.","issue":"40","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3748\/wjg.v20.i40.14778","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T23:46:24Z","timestamp":1414453584000},"page":"14778","source":"Crossref","is-referenced-by-count":34,"title":["Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract"],"prefix":"10.3748","volume":"20","author":[{"given":"Mark","family":"Pines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00328.2012"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/path.4253"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20427"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01641"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1021\/jm990131e"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.02.040"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998;30:445-450.","DOI":"10.1016\/S0306-3623(97)00307-8"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pines M, Vlodavsky I, Nagler A. Halofuginone: From veterinary use to human therapy. Drug Develop Res 2000;50:371-378.","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<371::AID-DDR19>3.0.CO;2-R"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.3.1.11"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996;52:1057-1063.","DOI":"10.1016\/0006-2952(96)00427-3"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Pines M, Domb A, Ohana M, Inbar J, Genina O, Alexiev R, Nagler A. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol 2001;62:1221-1227.","DOI":"10.1016\/S0006-2952(01)00753-5"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2008.06.386"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01690"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181967670"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, Bruck R, Spira G, Nagler A, Kawada N. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 2007;328:153-166.","DOI":"10.1007\/s00441-006-0330-1"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.01.003"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e31828a49e3"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1172638"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022770"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.790"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nature11774"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nature04754"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082286"},{"key":"ref24","unstructured":"Nunes AC, Rom\u00e3ozinho JM, Pontes JM, Rodrigues V, Ferreira M, Gomes D, Freitas D. Risk factors for stricture development after caustic ingestion. Hepatogastroenterology 2002;49:1563-1566."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i25.3918"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70160-8"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Oz&ccedil;elik MF, Pekmezci S, Saribeyo\u011flu K, Unal E, G&uuml;m&uuml;\u015fta\u015f K, Do\u011fusoy G. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury. Am J Surg 2004;187:257-260.","DOI":"10.1016\/j.amjsurg.2003.11.008"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000176551.09051.f2"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-010-1242-y"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-013-3210-2"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 2000;164:1776-1780.","DOI":"10.1016\/S0022-5347(05)67105-4"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, Pines M. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions. Ann Surg 1998;227:575-582.","DOI":"10.1097\/00000658-199804000-00021"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2010.234"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Nagler A, Genina O, Lavelin I, Ohana M, Pines M. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am J Obstet Gynecol 1999;180:558-563.","DOI":"10.1016\/S0002-9378(99)70254-1"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Eliashar R, Ochana M, Maly B, Pines M, Sichel JY, Nagler A. Halofuginone prevents subglottic stenosis in a canine model. Ann Otol Rhinol Laryngol 2006;115:382-386.","DOI":"10.1177\/000348940611500511"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130246"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.01.002"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013;5:217-230.","DOI":"10.2741\/S368"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00344"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2007"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.003"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11413002"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 2013;144:1210-1219.","DOI":"10.1053\/j.gastro.2012.11.037"},{"key":"ref44","unstructured":"Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmouli&egrave;re A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006;38:135-151."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009;25:223-229.","DOI":"10.1097\/MOG.0b013e3283279668"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05206"},{"key":"ref47","unstructured":"Schuppan D, Koda M, Bauer M, Hahn EG. Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets? Acta Gastroenterol Belg 2008;63:366-370."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 1997;27:391-398.","DOI":"10.1016\/S0168-8278(97)80186-9"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-386.","DOI":"10.1053\/jhep.2001.21408"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Abu-Amara SN, Geiger B, Genina O, Monsonego-Ornan E, Pines M. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. J Hepatol 2004;40:269-277.","DOI":"10.1016\/j.jhep.2003.10.020"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082232"},{"key":"ref52","unstructured":"Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol Histopathol 2013;28:211-226."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999;68:1806-1809.","DOI":"10.1097\/00007890-199912150-00027"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003;9:417-425.","DOI":"10.1016\/S1083-8791(03)00151-4"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 2006;281:15090-15098.","DOI":"10.1074\/jbc.M600030200"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06539.x"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e32835f07e2"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/31945"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-009-0202-4"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i46.5083"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Nagasue N, Yukaya H, Ogawa Y, Kohno H, Nakamura T. Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg 1987;206:30-39.","DOI":"10.1097\/00000658-198707000-00005"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03853.x"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1080\/136518202760378425"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Kaido T, Yoshikawa A, Seto S, Yamaoka S, Furuyama H, Arii S, Takahashi Y, Imamura M. Pretreatment with soluble thrombomodulin prevents intrasinusoidal coagulation and liver dysfunction following extensive hepatectomy in cirrhotic rats. Thromb Haemost 1999;82:1302-1306.","DOI":"10.1055\/s-0037-1614380"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01687.x"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Luo SM, Liang LJ, Lai JM. Effects of recombinant human growth hormone on remnant liver after hepatectomy in hepatocellular carcinoma with cirrhosis. World J Gastroenterol 2004;10:1292-1296.","DOI":"10.3748\/wjg.v10.i9.1292"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02493.x"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Spira G, Mawasi N, Paizi M, Anbinder N, Genina O, Alexiev R, Pines M. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002;37:331-339.","DOI":"10.1016\/S0168-8278(02)00164-2"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001;108:349-355.","DOI":"10.1172\/JCI200113738"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/path.1554"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2012.01.002"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2008.30"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-005-0092-1"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Peng Y, Du K, Ramirez S, Diamond RH, Taub R. Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. J Biol Chem 1999;274:4513-4520.","DOI":"10.1074\/jbc.274.8.4513"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Mueller L, Broering DC, Meyer J, Vashist Y, Goettsche J, Wilms C, Rogiers X. The induction of the immediate-early-genes Egr-1, PAI-1 and PRL-1 during liver regeneration in surgical models is related to increased portal flow. J Hepatol 2002;37:606-612.","DOI":"10.1016\/S0168-8278(02)00238-6"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Werner SR, Lee PA, DeCamp MW, Crowell DN, Randall SK, Crowell PL. Enhanced cell cycle progression and down regulation of p21(Cip1\/Waf1) by PRL tyrosine phosphatases. Cancer Lett 2003;202:201-211.","DOI":"10.1016\/S0304-3835(03)00517-2"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M206407200"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002;35:S79-S85.","DOI":"10.1097\/00004836-200211002-00003"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.06.010"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Okita K, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002;62 Suppl 1:24-28.","DOI":"10.1159\/000048272"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225-237.","DOI":"10.1016\/S0168-8278(00)80428-6"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Menke A, Adler G. TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer 2002;31:41-46.","DOI":"10.1385\/IJGC:31:1-3:41"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Go VL, Gukovskaya A, Pandol SJ. Alcohol and pancreatic cancer. Alcohol 2005;35:205-211.","DOI":"10.1016\/j.alcohol.2005.03.010"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1159\/000063165"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, Pines M, Ilan Y. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 2004;40:1397-1403.","DOI":"10.1016\/j.ejca.2003.11.036"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Bi&egrave;che I, Pines M, Rosenbaum J. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 2006;8:312-318.","DOI":"10.1593\/neo.05796"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181da8aa3"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041833"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1999;1:321-329.","DOI":"10.1038\/sj.neo.7900043"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10059"},{"key":"ref91","unstructured":"Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, Neeman M, Pines M, Nagler A. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 2003;9:3788-3793."},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, Genina O, Pines M. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol 2005;174:1527-1531.","DOI":"10.1097\/01.ju.0000179218.16587.d2"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0468"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00414.2010"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v20\/i40\/14778.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T14:23:49Z","timestamp":1565965429000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v20\/i40\/14778.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":94,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v20.i40.14778","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}